| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| Torin 1; Torin 1 | CFN60098 | 1222998-36-8 | C35H28F3N5O2 = 607.62 | 5mg | QQ客服：1413575084 |
| 沙帕色替; Sapanisertib (MLN0128) | CFN60099 | 1224844-38-5 | C15H15N7O = 309.33 | 5mg | QQ客服：2056216494 |
| Thiazovivin; Thiazovivin | CFN60100 | 1226056-71-8 | C15H13N5OS = 311.36 | 5mg | QQ客服：215959384 |
| Berzosertib (VE-822); Berzosertib (VE-822) | CFN60101 | 1232416-25-9 | C24H25N5O3S = 463.55 | 5mg | QQ客服：215959384 |
| Wnt-C59; Wnt-C59 | CFN60102 | 1243243-89-1 | C25H21N3O = 379.45 | 5mg | QQ客服：2159513211 |
| LGK-974 (WNT974); LGK-974 (WNT974) | CFN60103 | 1243244-14-5 | C23H20N6O = 396.44 | 5mg | QQ客服：1457312923 |
| Tubastatin A; Tubastatin A | CFN60104 | 1252003-15-8 | C20H21N3O2 = 335.4 | 5mg | QQ客服：1413575084 |
| 艾乐替尼; Alectinib (CH5424802) | CFN60105 | 1256580-46-7 | C30H34N4O2 = 482.62 | 5mg | QQ客服：2159513211 |
| BAPTA-AM; BAPTA-AM | CFN60106 | 126150-97-8 | C34H40N2O18 = 764.68 | 5mg | QQ客服：1413575084 |
| 氟维司琼; Fulvestrant | CFN60107 | 129453-61-8 | C32H47F5O3S = 606.77 | 5mg | QQ客服：1457312923 |
| 维替泊芬; Verteporfin | CFN60108 | 129497-78-5 | C41H42N4O8 = 718.79 | 5mg | QQ客服：3257982914 |
| H 89 2HCl; H 89 2HCl | CFN60109 | 130964-39-5 | C20H20BrN3O2S.2HCl = 519.28 | 5mg | QQ客服：215959384 |
| Ricolinostat (ACY-1215); Ricolinostat (ACY-1215) | CFN60110 | 1316214-52-4 | C24H27N5O3 = 433.5 | 5mg | QQ客服：2056216494 |
| Bisindolylmaleimide I; Bisindolylmaleimide I (GF109203X) | CFN60111 | 133052-90-1 | C25H24N4O2 = 412.48 | 5mg | QQ客服：1413575084 |
| Go 6983; Go 6983 | CFN60112 | 133053-19-7 | C26H26N4O3 = 442.51 | 5mg | QQ客服：3257982914 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)